Soluble and Insoluble Yeast β-Glucan Differentially Affect Upper Respiratory Tract Infection in Marathon Runners: A Double-Blind, Randomized Placebo-Controlled Trial
Soluble and Insoluble Yeast β-Glucan Differentially Affect Upper Respiratory Tract Infection in Marathon Runners: A Double-Blind, Randomized Placebo-Controlled Trial
复制标题
DOI：
10.1089/jmf.2019.0076
复制
发表时间：
2019-10-01
影响因子：
2.4
通讯作者：
Liska, DeAnn J.
中科院分区：
文献类型：
--
作者：
Mah, Eunice;Kaden, Valerie N.;Liska, DeAnn J.
在之前的一项研究中，食用含有不溶性 β-葡聚糖的乳制品饮料可以减少马拉松运动员的上呼吸道感染 (URTI) 症状天数和严重程度。在这份报告中，我们通过提供马拉松运动员体内含有可溶性 β-葡聚糖和 URTI 的乳制品饮料的数据来扩展我们之前的发现。参加 2017 年奥斯汀马拉松的健康成年人在马拉松比赛前 45 天、比赛当天和比赛后 45 天（总共 91 天）饮用含有 250 毫克不溶性（n = 69）或可溶性（n = 76）面包酵母 β-葡聚糖（Wellmune (R)）或安慰剂（n = 133）的乳制品饮料（250 mL/天）。参与者完成了每日在线调查，评估依从性和 URTI 症状，这些调查使用杰克逊指数进行评估并由研究医生确认。与安慰剂组相比，不溶性酵母 β-葡聚糖组的 URTI 总严重程度显着降低，但可溶性酵母 β-葡聚糖组和安慰剂组之间没有差异。与安慰剂组相比，不溶性和可溶性酵母β-葡聚糖组的鼻分泌物严重程度均显着降低。此外，与安慰剂组相比，不溶性酵母β-葡聚糖组的喉咙痛严重程度较低，但可溶性酵母β-葡聚糖组则不然。与安慰剂组相比，不溶性酵母 β-葡聚糖组（而非可溶性酵母 β-葡聚糖组）也报告了更少的 URTI 症状天数。结果表明，掺入食物基质中的可溶性和不溶性酵母β-葡聚糖对马拉松运动员运动诱发的上呼吸道感染有不同的影响。
In a previous study, consumption of a dairy beverage incorporating insoluble beta-glucan decreased upper respiratory tract infection (URTI) symptomatic days and severity in marathon runners. In this report, we extended our previous findings by presenting data on a dairy beverage containing soluble beta-glucan and URTI in marathon runners. Healthy adults running in the 2017 Austin Marathon consumed dairy beverages (250 mL/day) containing 250 mg of insoluble (n = 69) or soluble (n = 76) baker's yeast beta-glucan (Wellmune (R)) or placebo (n = 133) for the 45 days before, day of, and 45 days after the marathon (91 days total). Participants completed a daily online survey assessing compliance and URTI symptoms, which were evaluated using the Jackson Index and confirmed by the study physician. Total severity of URTI was significantly lower in the insoluble yeast beta-glucan group compared to the placebo group, but was not different between the soluble yeast beta-glucan group and placebo group. Severity ratings for nasal discharge were significantly lower in both the insoluble and soluble yeast beta-glucan groups compared to the placebo group. Additionally, severity rating for sore throat was lower in the insoluble, but not the soluble yeast beta-glucan group compared to the placebo group. The insoluble yeast beta-glucan group, but not the soluble yeast beta-glucan group also reported fewer URTI symptomatic days compared to the placebo group. The results suggest that soluble and insoluble yeast beta-glucan, incorporated into a food matrix, differentially affected exercise-induced URTI in marathon runners.